Synthetic Genomics Asset Acquisition (Details) - USD ($)								1 Months Ended	3 Months Ended
	Feb. 28, 2021	Jan. 31, 2021	Feb. 29, 2020	Jan. 31, 2020	Feb. 28, 2019	Jan. 31, 2019	Feb. 28, 2018	Feb. 28, 2018	Mar. 31, 2020	Mar. 31, 2019	Jun. 30, 2019	May 09, 2019	May 08, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability, fair value									$ 0					$ 1,100,000
Derivative liability										$ 1,157,000	$ 0			$ 1,117,000
Gain on derivative liability										(40,000)
Interest expense									159,000	$ 306,000
Synthetic Genomics Inc [Member] | C3J [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash paid for productive assets							$ 8,000,000	$ 8,000,000
Cash paid acquisition of assets	$ 5,000,000		$ 1,000,000	$ 1,000,000	$ 1,000,000	$ 1,000,000	1,000,000
Issuance of common stock and conversion of deferred consideration for asset acquisition							$ 27,000,000
Percentage of fully diluted capitalized for issuance of common stock								10.00%
Maximum potential milestone payments								$ 39,500,000
Derivative liability, fair value												$ 0	$ 2,800,000
Interest expense									$ 40,000
Equity payment obligation									516,976
Synthetic Genomics Inc [Member] | C3J [Member] | Scenario, Plan [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash paid acquisition of assets		$ 2,000,000